Sertraline in children and adolescents with obsessive-compulsive disorder

A multicenter randomized controlled trial

John S. March, Joseph Biederman, Robert Wolkow, Allan Safferman, Jack Mardekian, Edwin H. Cook, Neal R. Cutler, Roberto Dominguez, James Ferguson, Betty Muller, Robert Riesenberg, Murray Rosenthal, Floyd R. Sallee, Karen Wagner

Research output: Contribution to journalArticle

357 Citations (Scopus)

Abstract

Context. - The serotonin reuptake inhibitors are the treatment of choice for patients with obsessive-compulsive disorder; however, empirical support for this assertion has been weaker for children and adolescents than for adults. Objective. - To evaluate the safety and efficacy of the selective serotonin reuptake inhibitor sertraline hydrochloride in children and adolescents with obsessive-compulsive disorder. Design. - Randomized, double- blind, placebo-controlled trial. Patients. - One hundred eighty-seven patients: 107 children aged 6 to 12 years and 80 adolescents aged 13 to 17 years randomized to receive either sertraline (53 children, 39 adolescents) or placebo (54 children, 41 adolescents). Setting. - Twelve US academic and community clinics with experience conducting randomized controlled trials. Intervention. - Sertraline hydrochloride was titrated to a maximum of 200 mg/d during the first 4 weeks of double-blind therapy, after which patients continued to receive this dosage of medication for 8 more weeks. Control patients received placebo. Main Outcome Measures. - The Children's Yale- Brown Obsessive Compulsive Scale (CY-BOCS), the National Institute of Mental Health Global Obsessive Compulsive Scale (NIMH GOCS), and the NIMH Clinical Global Impressions of Severity of Illness (CGI-S) and Improvement (CGI-I) rating scales. Results. - In intent-to-treat analyses, patients treated with sertraline showed significantly greater improvement than did placebo-treated patients on the CY-BOCS (adjusted mean, -6.8 vs -3.4, respectively; P=.005), the NIMH GOCS (-2.2 vs -1.3, respectively; P = .02), and the CGI-I (2.7 vs 3.3, respectively; P = .002) scales. Significant differences in efficacy between sertraline and placebo emerged at week 3 and persisted for the duration of the study. Based on CGI-I ratings at end point, 42% of patients receiving sertraline and 26% of patients receiving placebo were very much or much improved. Neither age nor sex predicted response to treatment. The incidence of insomnia nausea, agitation, and tremor were significantly greater in patients receiving sertraline; 12 (13%) of 92 sertraline-treated patients and 3 (3.2%) of 95 placebo-treated patients discontinued prematurely because of adverse medical events (P = .02). No clinically meaningful abnormalities were apparent on vital sign determinations, laboratory findings, or electrocardiographic measurements. Conclusion. - Sertraline appears to be a safe and effective short-term treatment for children and adolescents with obsessive-compulsive disorder.

Original languageEnglish (US)
Pages (from-to)1752-1756
Number of pages5
JournalJournal of the American Medical Association
Volume280
Issue number20
StatePublished - Nov 25 1998

Fingerprint

Sertraline
Obsessive-Compulsive Disorder
Randomized Controlled Trials
Placebos
National Institute of Mental Health (U.S.)
Serotonin Uptake Inhibitors
Vital Signs
Sleep Initiation and Maintenance Disorders
Tremor
Therapeutics
Nausea

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sertraline in children and adolescents with obsessive-compulsive disorder : A multicenter randomized controlled trial. / March, John S.; Biederman, Joseph; Wolkow, Robert; Safferman, Allan; Mardekian, Jack; Cook, Edwin H.; Cutler, Neal R.; Dominguez, Roberto; Ferguson, James; Muller, Betty; Riesenberg, Robert; Rosenthal, Murray; Sallee, Floyd R.; Wagner, Karen.

In: Journal of the American Medical Association, Vol. 280, No. 20, 25.11.1998, p. 1752-1756.

Research output: Contribution to journalArticle

March, JS, Biederman, J, Wolkow, R, Safferman, A, Mardekian, J, Cook, EH, Cutler, NR, Dominguez, R, Ferguson, J, Muller, B, Riesenberg, R, Rosenthal, M, Sallee, FR & Wagner, K 1998, 'Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial', Journal of the American Medical Association, vol. 280, no. 20, pp. 1752-1756.
March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH et al. Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial. Journal of the American Medical Association. 1998 Nov 25;280(20):1752-1756.
March, John S. ; Biederman, Joseph ; Wolkow, Robert ; Safferman, Allan ; Mardekian, Jack ; Cook, Edwin H. ; Cutler, Neal R. ; Dominguez, Roberto ; Ferguson, James ; Muller, Betty ; Riesenberg, Robert ; Rosenthal, Murray ; Sallee, Floyd R. ; Wagner, Karen. / Sertraline in children and adolescents with obsessive-compulsive disorder : A multicenter randomized controlled trial. In: Journal of the American Medical Association. 1998 ; Vol. 280, No. 20. pp. 1752-1756.
@article{0db3aa3a282546949c60300b7cb922a3,
title = "Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial",
abstract = "Context. - The serotonin reuptake inhibitors are the treatment of choice for patients with obsessive-compulsive disorder; however, empirical support for this assertion has been weaker for children and adolescents than for adults. Objective. - To evaluate the safety and efficacy of the selective serotonin reuptake inhibitor sertraline hydrochloride in children and adolescents with obsessive-compulsive disorder. Design. - Randomized, double- blind, placebo-controlled trial. Patients. - One hundred eighty-seven patients: 107 children aged 6 to 12 years and 80 adolescents aged 13 to 17 years randomized to receive either sertraline (53 children, 39 adolescents) or placebo (54 children, 41 adolescents). Setting. - Twelve US academic and community clinics with experience conducting randomized controlled trials. Intervention. - Sertraline hydrochloride was titrated to a maximum of 200 mg/d during the first 4 weeks of double-blind therapy, after which patients continued to receive this dosage of medication for 8 more weeks. Control patients received placebo. Main Outcome Measures. - The Children's Yale- Brown Obsessive Compulsive Scale (CY-BOCS), the National Institute of Mental Health Global Obsessive Compulsive Scale (NIMH GOCS), and the NIMH Clinical Global Impressions of Severity of Illness (CGI-S) and Improvement (CGI-I) rating scales. Results. - In intent-to-treat analyses, patients treated with sertraline showed significantly greater improvement than did placebo-treated patients on the CY-BOCS (adjusted mean, -6.8 vs -3.4, respectively; P=.005), the NIMH GOCS (-2.2 vs -1.3, respectively; P = .02), and the CGI-I (2.7 vs 3.3, respectively; P = .002) scales. Significant differences in efficacy between sertraline and placebo emerged at week 3 and persisted for the duration of the study. Based on CGI-I ratings at end point, 42{\%} of patients receiving sertraline and 26{\%} of patients receiving placebo were very much or much improved. Neither age nor sex predicted response to treatment. The incidence of insomnia nausea, agitation, and tremor were significantly greater in patients receiving sertraline; 12 (13{\%}) of 92 sertraline-treated patients and 3 (3.2{\%}) of 95 placebo-treated patients discontinued prematurely because of adverse medical events (P = .02). No clinically meaningful abnormalities were apparent on vital sign determinations, laboratory findings, or electrocardiographic measurements. Conclusion. - Sertraline appears to be a safe and effective short-term treatment for children and adolescents with obsessive-compulsive disorder.",
author = "March, {John S.} and Joseph Biederman and Robert Wolkow and Allan Safferman and Jack Mardekian and Cook, {Edwin H.} and Cutler, {Neal R.} and Roberto Dominguez and James Ferguson and Betty Muller and Robert Riesenberg and Murray Rosenthal and Sallee, {Floyd R.} and Karen Wagner",
year = "1998",
month = "11",
day = "25",
language = "English (US)",
volume = "280",
pages = "1752--1756",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "20",

}

TY - JOUR

T1 - Sertraline in children and adolescents with obsessive-compulsive disorder

T2 - A multicenter randomized controlled trial

AU - March, John S.

AU - Biederman, Joseph

AU - Wolkow, Robert

AU - Safferman, Allan

AU - Mardekian, Jack

AU - Cook, Edwin H.

AU - Cutler, Neal R.

AU - Dominguez, Roberto

AU - Ferguson, James

AU - Muller, Betty

AU - Riesenberg, Robert

AU - Rosenthal, Murray

AU - Sallee, Floyd R.

AU - Wagner, Karen

PY - 1998/11/25

Y1 - 1998/11/25

N2 - Context. - The serotonin reuptake inhibitors are the treatment of choice for patients with obsessive-compulsive disorder; however, empirical support for this assertion has been weaker for children and adolescents than for adults. Objective. - To evaluate the safety and efficacy of the selective serotonin reuptake inhibitor sertraline hydrochloride in children and adolescents with obsessive-compulsive disorder. Design. - Randomized, double- blind, placebo-controlled trial. Patients. - One hundred eighty-seven patients: 107 children aged 6 to 12 years and 80 adolescents aged 13 to 17 years randomized to receive either sertraline (53 children, 39 adolescents) or placebo (54 children, 41 adolescents). Setting. - Twelve US academic and community clinics with experience conducting randomized controlled trials. Intervention. - Sertraline hydrochloride was titrated to a maximum of 200 mg/d during the first 4 weeks of double-blind therapy, after which patients continued to receive this dosage of medication for 8 more weeks. Control patients received placebo. Main Outcome Measures. - The Children's Yale- Brown Obsessive Compulsive Scale (CY-BOCS), the National Institute of Mental Health Global Obsessive Compulsive Scale (NIMH GOCS), and the NIMH Clinical Global Impressions of Severity of Illness (CGI-S) and Improvement (CGI-I) rating scales. Results. - In intent-to-treat analyses, patients treated with sertraline showed significantly greater improvement than did placebo-treated patients on the CY-BOCS (adjusted mean, -6.8 vs -3.4, respectively; P=.005), the NIMH GOCS (-2.2 vs -1.3, respectively; P = .02), and the CGI-I (2.7 vs 3.3, respectively; P = .002) scales. Significant differences in efficacy between sertraline and placebo emerged at week 3 and persisted for the duration of the study. Based on CGI-I ratings at end point, 42% of patients receiving sertraline and 26% of patients receiving placebo were very much or much improved. Neither age nor sex predicted response to treatment. The incidence of insomnia nausea, agitation, and tremor were significantly greater in patients receiving sertraline; 12 (13%) of 92 sertraline-treated patients and 3 (3.2%) of 95 placebo-treated patients discontinued prematurely because of adverse medical events (P = .02). No clinically meaningful abnormalities were apparent on vital sign determinations, laboratory findings, or electrocardiographic measurements. Conclusion. - Sertraline appears to be a safe and effective short-term treatment for children and adolescents with obsessive-compulsive disorder.

AB - Context. - The serotonin reuptake inhibitors are the treatment of choice for patients with obsessive-compulsive disorder; however, empirical support for this assertion has been weaker for children and adolescents than for adults. Objective. - To evaluate the safety and efficacy of the selective serotonin reuptake inhibitor sertraline hydrochloride in children and adolescents with obsessive-compulsive disorder. Design. - Randomized, double- blind, placebo-controlled trial. Patients. - One hundred eighty-seven patients: 107 children aged 6 to 12 years and 80 adolescents aged 13 to 17 years randomized to receive either sertraline (53 children, 39 adolescents) or placebo (54 children, 41 adolescents). Setting. - Twelve US academic and community clinics with experience conducting randomized controlled trials. Intervention. - Sertraline hydrochloride was titrated to a maximum of 200 mg/d during the first 4 weeks of double-blind therapy, after which patients continued to receive this dosage of medication for 8 more weeks. Control patients received placebo. Main Outcome Measures. - The Children's Yale- Brown Obsessive Compulsive Scale (CY-BOCS), the National Institute of Mental Health Global Obsessive Compulsive Scale (NIMH GOCS), and the NIMH Clinical Global Impressions of Severity of Illness (CGI-S) and Improvement (CGI-I) rating scales. Results. - In intent-to-treat analyses, patients treated with sertraline showed significantly greater improvement than did placebo-treated patients on the CY-BOCS (adjusted mean, -6.8 vs -3.4, respectively; P=.005), the NIMH GOCS (-2.2 vs -1.3, respectively; P = .02), and the CGI-I (2.7 vs 3.3, respectively; P = .002) scales. Significant differences in efficacy between sertraline and placebo emerged at week 3 and persisted for the duration of the study. Based on CGI-I ratings at end point, 42% of patients receiving sertraline and 26% of patients receiving placebo were very much or much improved. Neither age nor sex predicted response to treatment. The incidence of insomnia nausea, agitation, and tremor were significantly greater in patients receiving sertraline; 12 (13%) of 92 sertraline-treated patients and 3 (3.2%) of 95 placebo-treated patients discontinued prematurely because of adverse medical events (P = .02). No clinically meaningful abnormalities were apparent on vital sign determinations, laboratory findings, or electrocardiographic measurements. Conclusion. - Sertraline appears to be a safe and effective short-term treatment for children and adolescents with obsessive-compulsive disorder.

UR - http://www.scopus.com/inward/record.url?scp=0032567055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032567055&partnerID=8YFLogxK

M3 - Article

VL - 280

SP - 1752

EP - 1756

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 20

ER -